Samsung Bioepis Selected as 'Asia-Pacific Company of the Year' at the Biosimilar Awards

Samsung Bioepis announced on the 14th that it was selected as the 'Asia-Pacific Company of the Year' at the 'Global Generic & Biosimilar Awards 2024' held in Milan, Italy on the 9th (local time).

The Global Generic & Biosimilar Awards is an annual awards event hosted by Scrip, a pharmaceutical industry information service company, recognizing companies that have achieved notable business performance in the generic and biosimilar industries.

Samsung Bioepis received the award in this category in recognition of its achievements in research, development, and commercialization across various fields this year as a leading company in the global biosimilar industry.

This year, Samsung Bioepis obtained approval for the biosimilar of the autoimmune disease treatment Stelara, named Fiztchiva, in Europe (April) and the United States (June), with the product launched in Europe in July. Additionally, Opufyz, a biosimilar of the eye disease treatment Eylea, was approved in the United States in May and recently received a positive opinion, a pre-approval stage, in Europe last month. Samsung Bioepis also developed Episcleer, a biosimilar of Soliris, a treatment for rare diseases such as paroxysmal nocturnal hemoglobinuria, which received approval in the United States in July.

Samsung Bioepis has continued its achievements at the Global Generic & Biosimilar Awards, having previously won 'Biosimilar Leading Company' in 2020, 'Asia-Pacific Company of the Year' in 2022 and 2023, as well as 'Regulatory Achievement of the Year' in 2023.

This content was produced with the assistance of AI translation services.